 "Glenmark receives US FDA approval for skin ointment lidocaine")
The US Food & Drug Administration (FDA) has granted final approval to Glenmark Pharmaceuticals for its skin treatment medication lidocaine ointment USP, 5%. The approved product is the generic version of AstraZeneca’s Xylocaine ointment.
“Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the US FDA for lidocaine ointment USP, 5%, the generic version of Xylocaine Ointment, 5% of AstraZeneca,” said Glenmark in a press statement.
Lidocaine ointment is used on the skin to stop itching and pain from certain skin conditions such as scrapes, minor burns, eczema, insect bites, etc.
According to IMS Health sales data for the 12 month period ending July 2016, the Xylocaine ointment (5%) market achieved annual sales of approximately $ 373 million.
Glenmark’s current portfolio consists of 109 products authorised for distribution in the US marketplace and 62 ANDA’s pending approval with the US FDA.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%